An interventional study of Cala Trio in Essential Tremor, sponsored by Cala Health, Inc.. Completed at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Cala Health, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 146 studies in Essential Tremor with a site in United States — 40 open to participants now, 46 under way, 1 of them phase 3. Essential Tremor · United States.
Among the 146 studies in Essential Tremor with a site in United States, this one is the 5th largest by enrollment of the 104 interventional ones that give a count, is one of 12 that started in 2021, is one of 60 with no phase, and was the 119th registered.
272 studies on the registry are indexed under Essential Tremor; 75 are open to participants now.
Browse Essential Tremor studies →40 of the 146 studies in Essential Tremor with a site in United States are open now. Recruiting first, the newest first:
Encora, Inc. · Sites in United States
Ages 18+
AbbVie · Sites in United States, Canada
Ages 18–85
University of California, Los Angeles · Sites in United States
Ages 18–90
CND Life Sciences · Sites in United States
Ages 50–85
Boston University Charles River Campus · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 61 Essential Tremor studies recruiting now, 32 (52%) set no upper age limit and 5 (8%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
146 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 27 · Phase 3 5 · Phase 4 5
First in 2000; this study’s year is marked. 12 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 276 is above the median of 25 across 189 interventional studies indexed under Essential Tremor.
Median enrollment 30 across the 104 interventional studies, 81 across the 41 observational. Of the 86 that completed or were terminated, 39 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 146 have an industry lead sponsor. The 10 most frequent:
Cala Health, Inc. is the lead sponsor of 8 studies on the registry; none are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.
Cala Health, Inc. has 5 studies filed under Essential Tremor — fewer than ten, so there is no comparison to draw.
13 of the studies in Essential Tremor with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03778060Mayo ClinicLong-Term Transcutaneous Stimulation and Essential Tremor: A PET Study | 2026-12 |
| NCT07599592University of California, Los AngelesOpen Label Study for the Use of Low Intensity Focused Ultrasound for Essential Tremor | 2026-12-31 |
| NCT07428447CND Life SciencesAnalysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease | 2027-02 |
| NCT04286308Massachusetts General HospitalCortical-Basal Ganglia Speech Networks | 2027-02 |
| NCT02553525Duke UniversityEffects of Stimulation Patterns of Deep Brain Stimulation | 2027-03 |
Add all 13 to your calendar (.ics) → With an account.
Among the 146 studies in Essential Tremor with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study objective is to evaluate hand tremor relief in the treated hand following stimulation with the Cala Trio Device in adults with essential tremor, and healthcare resource utilization and total healthcare costs over a 12-month period.
This is a prospective, randomized, dual arm, pragmatic trial in a real-world setting to evaluate the effectiveness and health economics outcomes of the Cala Trio device in reducing hand tremor and improving quality of life as measured by the Bain and Findley Activities of Daily Living (ADL) score relevant to the stimulated upper limb. Healthcare resources utilization and total all-cause healthcare will also be evaluated. The study will recruit approximately 300 patients: 150 in the intervention arm (Cala Trio device)and 150 patients in the standard of care (SOC) arm. Subjects will be randomized to either the intervention arm or the standard of care arm (1:1).Subjects in the SOC arm will be asked to measure their tremor severity by doing daily postural holds with the Cala Trio device without actual stimulation. Subjects in the intervention arm will wear the device at home for a period of 12 months, during which they will deliver 40 min stimulation sessions, which can be started and stopped on demand. After the first month, the subjects who were randomized to the SOC arm will cross over to the intervention arm.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Baseline tremor power without stimulation (SOC arm) over the first month of the study. Subjects in the SOC arm will be asked to measure their tremor severity by doing daily postural holds with the Cala Trio device without actual stimulation.
Tremor power after stimulation with Cala Trio. Subjects in the intervention arm will wear the device at home for a period of 12 months, during which they will deliver 40 min stimulation sessions, which can be started and stopped on demand.
Device: Cala Trio
transcutaneous afferent patterned stimulation (TAPS)
Change in tremor power
Difference in tremor power after stimulation with Cala Trio (treated arm) and baseline tremor power without stimulation (SOC arm) over the first month of the study. Prior to and immediately after each of the first 40 stimulation sessions and every 7th session thereafter, the Cala Trio will direct the patient to perform postural hold tremor tasks to measure tremor power pre and post stimulation. The SOC arm will perform a tremor measurement only, without any stimulation sessions, for 1 month.
Time frame: 1 Month
Bain & Findley Activities of Daily Living (BF-ADL) scale subset score
BF-ADL subset score relevant to the stimulated upper limb. The subset score is the sum of 8 rated tasks. Each task is rated 1 to 4, where a higher score indicates more severe tremor. Minimum subset score = 8; Maximum subset score = 32. Improvements in BF-ADL scores will be measured from baseline over the 12 months study duration.
Time frame: 12 Months
Tremor power improvement ratio (TPIR)
TPIR is defined as the ratio of pre- to post-stimulation tremor power. Per-patient median TPIR over first, second, third, and fourth quarters of the study (i.e., months 1 - 3, 4 - 6, etc.) will be assessed.
Time frame: 12 Months
Ran from Apr 2021 to primary completion in Mar 2024, 34 months.
Of 95 interventional studies with no phase under Essential Tremor, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 93. This study's 34 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cala Health, Inc.